Crude Oil Falls 1%; US Services PMI Declines In June
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Should l Buy HIMS?
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Nasdaq Composite gaining over 50 points, while the S&P Global US services PMI fell to 53.1 in June, slightly above market expectations.
Sector Movements and Notable Stocks: Consumer discretionary shares rose by 1.6%, while health care stocks declined. Significant stock movements included Impact BioMedical's shares surging 386% due to a merger announcement, and Hims & Hers Health's shares dropping 28% after a collaboration termination.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 42.88 USD with a low forecast of 29.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
7 Hold
3 Sell
Hold
Current: 23.480
Low
29.00
Averages
42.88
High
85.00
Current: 23.480
Low
29.00
Averages
42.88
High
85.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Sues Hims for Patent Infringement
- Patent Infringement Lawsuit: Novo Nordisk (NVO) filed a lawsuit against Hims & Hers (HIMS) on Monday, alleging infringement of U.S. Patent 8,129,343 related to its weight loss therapy semaglutide, which could undermine Novo's competitive advantage in the market.
- Marketing Violations: Novo claims HIMS unlawfully mass-marketed unapproved versions of semaglutide drugs, including the newly launched Wegovy oral obesity therapy, potentially misleading consumers and healthcare professionals, thus affecting the drug's market image.
- Legal Threats and Response: Following Novo's legal threats and regulatory pushback, HIMS announced it would cease offering copycat versions of the drug on its platform, demonstrating Novo's firm stance on protecting its intellectual property, which may impact HIMS's market strategy.
- Industry Impact: HIMS's promotional activities have drawn significant industry attention, especially amid a GLP-1 drug shortage, and Novo's lawsuit could have far-reaching implications for the competitive landscape of the weight loss drug market.
See More
Novo Nordisk Sues Hims & Hers for Consumer Deception
- Lawsuit Initiated: Novo Nordisk has filed a lawsuit against Hims & Hers, seeking a permanent ban on the sale of unapproved compounded drugs, aiming to protect its intellectual property and public safety, highlighting the company's commitment to market regulation.
- FDA Warning Impact: The U.S. FDA warned last week of a crackdown on GLP-1 active pharmaceutical ingredients intended for non-FDA-approved compounded drugs, prompting Hims & Hers to cease offering the $49 compounded version of Novo's Wegovy, indicating a tightening regulatory environment's direct impact on the market.
- Analyst Warnings: Citi analysts cut Hims & Hers' price target from $30 to $16.5, reflecting concerns over the company's sales risks, with a 25% probability of losing all weight loss drug sales, indicating a pessimistic sentiment regarding its future prospects.
- Market Reaction: Novo Nordisk's shares rose over 5% in pre-market trading on Monday, while Hims & Hers shares fell more than 19%, demonstrating increased investor confidence in Novo Nordisk and concerns over Hims & Hers' legal risks.
See More
Tech Companies Stock Price Movements Analysis
- Oracle Stock Rise: Oracle shares increased by 2% after DA Davidson upgraded its rating from neutral to buy, with analysts believing that a revamped OpenAI will regain its position as Google's top competitor, enhancing collaboration potential with Oracle.
- STMicroelectronics Partnership Expansion: STMicroelectronics saw a 7% stock increase following a multi-billion-dollar partnership announcement with Amazon Web Services to support infrastructure for cloud and AI data centers, which is expected to drive future revenue growth for the company.
- Kroger CEO Transition: Kroger's shares jumped nearly 5% after the Wall Street Journal reported that former Walmart executive Greg Foran will be appointed as the new CEO, indicating a potential strategic shift that could enhance the company's performance in a competitive retail market.
- Hims & Hers Health Crisis: Hims & Hers stock plummeted 18% after it withdrew its copycat weight-loss pill following legal threats from Novo Nordisk, highlighting the importance of intellectual property in the market and potentially impacting Hims & Hers' future product strategy.
See More
Novo Nordisk Sues Hims Over Patent Infringement
- Escalating Legal Action: Novo Nordisk has filed a lawsuit seeking a permanent ban on Hims from selling compounded drugs that infringe its patents while also pursuing damages, demonstrating its commitment to defending its interests in the rapidly growing obesity drug market.
- Intensified Market Competition: Hims planned to offer its newly launched obesity pill at $49 per month, significantly lower than Novo's Wegovy, but has decided to halt sales after facing scrutiny from regulators and legal threats from the Danish drugmaker.
- Patient Safety Concerns: Novo accused Hims of deceiving patients by marketing unapproved drugs that lack FDA verification, highlighting the critical importance of regulatory standards to ensure drug safety and efficacy.
- FDA Investigation: The FDA has announced plans to take legal action against Hims, including restricting access to drug ingredients and referring the company to the Department of Justice for potential violations, further complicating Hims' legal challenges.
See More
Novo Nordisk Sues Hims for Patent Infringement
- Patent Infringement Lawsuit: Novo Nordisk has filed a lawsuit against U.S. telehealth company Hims, alleging patent infringement and seeking a court order to permanently ban Hims from selling unapproved compounded drugs, demonstrating Novo Nordisk's strong commitment to protecting its intellectual property.
- Damages Claim: The Danish drugmaker is also seeking damages in the lawsuit, indicating its response to Hims' cancellation of a $49 weight-loss pill launch, which underscores the company's determination to maintain competitive market conditions.
- Market Dynamics Shift: Hims' cancellation of the weight-loss pill launch prior to the lawsuit reflects the sensitivity of the market to patent protections and its impact on new product introductions, potentially diminishing Hims' competitiveness in the weight-loss drug market.
- Industry Implications: This lawsuit could have broad implications for the digital health sector, particularly regarding compliance in drug development and sales, prompting other companies to place greater emphasis on patent protection and legal risk management.
See More
S&P 500 Futures Drop in Pre-Market Session; Kyndryl Holdings and Hims & Hers Health Underperform
Market Opening: U.S. stock markets are set to open in two hours.
Dynatrace Inc. Performance: Dynatrace Inc. (DT) saw a 13.9% increase in pre-market trading.
Kroger Co. Performance: Kroger Co. (KR) experienced a 5.0% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Novo Nordisk Sues Hims for Patent Infringement
- Patent Infringement Lawsuit: Novo Nordisk (NVO) filed a lawsuit against Hims & Hers (HIMS) on Monday, alleging infringement of U.S. Patent 8,129,343 related to its weight loss therapy semaglutide, which could undermine Novo's competitive advantage in the market.
- Marketing Violations: Novo claims HIMS unlawfully mass-marketed unapproved versions of semaglutide drugs, including the newly launched Wegovy oral obesity therapy, potentially misleading consumers and healthcare professionals, thus affecting the drug's market image.
- Legal Threats and Response: Following Novo's legal threats and regulatory pushback, HIMS announced it would cease offering copycat versions of the drug on its platform, demonstrating Novo's firm stance on protecting its intellectual property, which may impact HIMS's market strategy.
- Industry Impact: HIMS's promotional activities have drawn significant industry attention, especially amid a GLP-1 drug shortage, and Novo's lawsuit could have far-reaching implications for the competitive landscape of the weight loss drug market.
See More
Novo Nordisk Sues Hims & Hers for Consumer Deception
- Lawsuit Initiated: Novo Nordisk has filed a lawsuit against Hims & Hers, seeking a permanent ban on the sale of unapproved compounded drugs, aiming to protect its intellectual property and public safety, highlighting the company's commitment to market regulation.
- FDA Warning Impact: The U.S. FDA warned last week of a crackdown on GLP-1 active pharmaceutical ingredients intended for non-FDA-approved compounded drugs, prompting Hims & Hers to cease offering the $49 compounded version of Novo's Wegovy, indicating a tightening regulatory environment's direct impact on the market.
- Analyst Warnings: Citi analysts cut Hims & Hers' price target from $30 to $16.5, reflecting concerns over the company's sales risks, with a 25% probability of losing all weight loss drug sales, indicating a pessimistic sentiment regarding its future prospects.
- Market Reaction: Novo Nordisk's shares rose over 5% in pre-market trading on Monday, while Hims & Hers shares fell more than 19%, demonstrating increased investor confidence in Novo Nordisk and concerns over Hims & Hers' legal risks.
See More
Tech Companies Stock Price Movements Analysis
- Oracle Stock Rise: Oracle shares increased by 2% after DA Davidson upgraded its rating from neutral to buy, with analysts believing that a revamped OpenAI will regain its position as Google's top competitor, enhancing collaboration potential with Oracle.
- STMicroelectronics Partnership Expansion: STMicroelectronics saw a 7% stock increase following a multi-billion-dollar partnership announcement with Amazon Web Services to support infrastructure for cloud and AI data centers, which is expected to drive future revenue growth for the company.
- Kroger CEO Transition: Kroger's shares jumped nearly 5% after the Wall Street Journal reported that former Walmart executive Greg Foran will be appointed as the new CEO, indicating a potential strategic shift that could enhance the company's performance in a competitive retail market.
- Hims & Hers Health Crisis: Hims & Hers stock plummeted 18% after it withdrew its copycat weight-loss pill following legal threats from Novo Nordisk, highlighting the importance of intellectual property in the market and potentially impacting Hims & Hers' future product strategy.
See More
Novo Nordisk Sues Hims Over Patent Infringement
- Escalating Legal Action: Novo Nordisk has filed a lawsuit seeking a permanent ban on Hims from selling compounded drugs that infringe its patents while also pursuing damages, demonstrating its commitment to defending its interests in the rapidly growing obesity drug market.
- Intensified Market Competition: Hims planned to offer its newly launched obesity pill at $49 per month, significantly lower than Novo's Wegovy, but has decided to halt sales after facing scrutiny from regulators and legal threats from the Danish drugmaker.
- Patient Safety Concerns: Novo accused Hims of deceiving patients by marketing unapproved drugs that lack FDA verification, highlighting the critical importance of regulatory standards to ensure drug safety and efficacy.
- FDA Investigation: The FDA has announced plans to take legal action against Hims, including restricting access to drug ingredients and referring the company to the Department of Justice for potential violations, further complicating Hims' legal challenges.
See More
Novo Nordisk Sues Hims for Patent Infringement
- Patent Infringement Lawsuit: Novo Nordisk has filed a lawsuit against U.S. telehealth company Hims, alleging patent infringement and seeking a court order to permanently ban Hims from selling unapproved compounded drugs, demonstrating Novo Nordisk's strong commitment to protecting its intellectual property.
- Damages Claim: The Danish drugmaker is also seeking damages in the lawsuit, indicating its response to Hims' cancellation of a $49 weight-loss pill launch, which underscores the company's determination to maintain competitive market conditions.
- Market Dynamics Shift: Hims' cancellation of the weight-loss pill launch prior to the lawsuit reflects the sensitivity of the market to patent protections and its impact on new product introductions, potentially diminishing Hims' competitiveness in the weight-loss drug market.
- Industry Implications: This lawsuit could have broad implications for the digital health sector, particularly regarding compliance in drug development and sales, prompting other companies to place greater emphasis on patent protection and legal risk management.
See More
S&P 500 Futures Drop in Pre-Market Session; Kyndryl Holdings and Hims & Hers Health Underperform
Market Opening: U.S. stock markets are set to open in two hours.
Dynatrace Inc. Performance: Dynatrace Inc. (DT) saw a 13.9% increase in pre-market trading.
Kroger Co. Performance: Kroger Co. (KR) experienced a 5.0% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
